Piper Jaffray analyst Danielle Brill raised her price target for Acadia Pharmaceuticals to $56 from $35 and maintained an Overweight rating after the company's Phase 3 HARMONY study of pima in DRP "hit the high-stats bar" required to end the study early for efficacy, saying shares are now significantly de-risked. Brill says the outcome is a "homerun" for Acadia, and while she says positive results were not unexpected, she did think the interim's stats threshold would be difficult to beat. She sees approval by year-end 2020, saying that if approved, Nuplazid will serve as a standalone drug for DRP, which she estimates at a ~$1.8B opportunity at peak.